Will delaying the administration of Ustekinumab for 9 days affect the efficacy?

Ustekinumab is a drug that targets interleukin-12 (IL-12 ) and Monoclonal antibodies to interleukin-23 (IL-23) are mainly used to treat autoimmune diseases such as psoriasis and Crohn's disease. It is usually injected at regular intervals to maintain stable drug concentrations in the body to continuously control disease activity. Delaying the injection time, especially beyond the scheduled time, often causes patients to worry about whether the efficacy will be affected.

Delaying ustekinumab injection9 days theoretically has less impact on the efficacy. The half-life of ustekinumab is longer, about 3 or more, and the drug concentration in the body decreases slowly. Therefore, a short-term delayed injection generally will not cause rapid drug failure or significant rebound of the disease. However, the longer the delay, the drug concentration will gradually decrease, and disease control may fluctuate to some extent, so it is recommended to inject on time as much as possible.

If there is no obvious aggravation of symptoms or recurrence of skin lesions after delaying the injection, the patient can refill the dose as soon as possible under the guidance of a doctor and resume the normal injection rhythm. However, if the condition recurs or worsens, you need to consult a doctor promptly to evaluate whether the treatment plan needs to be adjusted, such as increasing the dose or shortening the injection interval.

In short, although a short-term delay of 9 days has limited impact on the efficacy of ustekinumab, it is still recommended that patients avoid delays as much as possible and maintain regular medication. At the same time, patients should pay attention to changes in their own condition, communicate with doctors in a timely manner to ensure stable treatment effects, and avoid disease fluctuations caused by irregular medication.

Reference materials:https://www.drugs.com